These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33758111)

  • 1. Prescribing the Buprenorphine Monoproduct for Adverse Effects of Buprenorphine-Naloxone.
    Grande LA
    J Addict Med; 2022 Jan-Feb 01; 16(1):4-6. PubMed ID: 33758111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine alone or with naloxone: Which is safer?
    Kelty E; Cumming C; Troeung L; Hulse G
    J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
    Gunderson EW; Hjelmström P; Sumner M;
    Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine/naloxone - one formulation that doesn't fit all: a case report.
    Braun HM; Taylor JL; Axelrath S
    Harm Reduct J; 2024 Jul; 21(1):143. PubMed ID: 39080714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost Analysis of Buprenorphine Extended-Release Injection Versus Sublingual Buprenorphine/Naloxone Tablets in a Correctional Setting.
    Wong JSH; Masson S; Huang A; Romm D; Fong M; Porter T; Sharifi N; Azar P; Mathew N
    J Correct Health Care; 2022 Dec; 28(6):368-371. PubMed ID: 36342953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sublingual buprenorphine-naloxone precipitated withdrawal-A case report with review of literature and clinical considerations.
    Bhatia G; Sarkar S
    Asian J Psychiatr; 2020 Oct; 53():102121. PubMed ID: 32460142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of opioid dependence with buprenorphine: current update.
    Soyka M
    Dialogues Clin Neurosci; 2017 Sep; 19(3):299-308. PubMed ID: 29302227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014-2020.
    Bach P; Bawa M; Grant C; Milloy MJ; Hayashi K
    Int J Drug Policy; 2022 Mar; 101():103545. PubMed ID: 34875527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film.
    Gunderson EW; Sumner M
    J Addict Med; 2016; 10(2):124-30. PubMed ID: 26918662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
    Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
    J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
    Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
    Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
    Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the evidence to explain pharmacological basis of injection (ab)use of buprenorphine-naloxone tablets.
    Modak T; Sarkar S; Balhara YPS
    J Opioid Manag; 2021; 17(7):141-152. PubMed ID: 34520035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
    Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
    Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost?
    Gregg J; Hartley J; Lawrence D; Risser A; Blazes C
    J Addict Med; 2023 Jan-Feb 01; 17(1):7-9. PubMed ID: 35913990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder.
    Enns B; Krebs E; Whitehurst DGT; Jutras-Aswad D; Le Foll B; Socias ME; Nosyk B;
    Drug Alcohol Depend; 2023 Jun; 247():109893. PubMed ID: 37120920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada.
    Iacono A; Wang T; Tadrous M; Campbell T; Kolla G; Leece P; Sproule B; Kleinman RA; Besharah J; Munro C; Doolittle M; Gomes T
    Drug Alcohol Depend; 2024 Jan; 254():111032. PubMed ID: 38043224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
    Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.